Phase II study of lapatinib and tegafur combination efficacy for the treatment of HER2+metastatic breast cancer.

被引：0
|
作者：
Manikhas, Alexey
Sharvashidze, Ineza O.
Kotkova, Tatjana N.
机构：
[1] City Clin Oncol Dispensary, St Petersburg, Russia
[2] State Clin Oncol Dispensary, St Petersburg, Russia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11086
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A PHASE II EVALUATION OF LAPATINIB (L) AND BEVACIZUMAB (B) IN HER2+METASTATIC BREAST CANCER (MBC)
    Dickler, M.
    Franco, S.
    Stopeck, A.
    Ma, W.
    Lyandres, J.
    Lahiri, S.
    Arbushites, M.
    Koehler, M.
    Rugo, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 65 - 65
  • [2] A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+metastatic breast cancer (MBC)
    Rugo, H. S.
    Franco, S.
    Munster, P.
    Stopeck, A.
    Ma, W.
    Lyandres, J.
    Lahiri, S.
    Arbushites, M.
    Koehler, M.
    Dickler, M. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Study of the combination gemcitabine and trastuzumab in the treatment of HER2+metastatic breast cancer
    Menjon-Beltran, S.
    Olivencia-Dueso, R.
    Gonzalez-Jimenez, E.
    Titos, M. J.
    BREAST CANCER RESEARCH, 2007, 9 (01)
  • [4] Multicenter observational study on adherence and acceptance of lapatinib treatment in patients with HER2+metastatic breast cancer
    Addeo, R.
    Vincenzi, B.
    Riccardi, F.
    Febbraro, A.
    Maiorino, L.
    Incoronato, P.
    Mabilia, R.
    Bianco, M.
    Russo, E.
    Pisano, A.
    Del Prete, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
    Hope S. Rugo
    A. Jo Chien
    Sandra X. Franco
    Alison T. Stopeck
    Alexa Glencer
    Soumi Lahiri
    Michael C. Arbushites
    Janet Scott
    John W. Park
    Clifford Hudis
    Ben Nulsen
    Maura N. Dickler
    Breast Cancer Research and Treatment, 2012, 134 : 13 - 20
  • [6] A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
    Rugo, Hope S.
    Chien, A. Jo
    Franco, Sandra X.
    Stopeck, Alison T.
    Glencer, Alexa
    Lahiri, Soumi
    Arbushites, Michael C.
    Scott, Janet
    Park, John W.
    Hudis, Clifford
    Nulsen, Ben
    Dickler, Maura N.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (01) : 13 - 20
  • [7] Phase I/II trial of ruxolitinib in combination with trastuzumab in HER2+metastatic breast cancer (MBC)
    Kalinsky, Kevin
    Lee, Shing
    Tiersten, Amy
    Makower, Della F.
    Cigler, Tessa
    Franks, Lauren
    Mundi, Prabhjot
    Chi, Dow-Chung
    Blumberg, Lauren
    Sender, Naomi
    Galazyn, Magdalena
    Hosi, Kristina
    Goel, Anupama
    Klein, Paula
    Andreopoulou, Eleni
    Sparano, Joseph
    Crew, Katherine D.
    Califano, Andrea
    Silva, Jose
    Hershman, Dawn L.
    CANCER RESEARCH, 2020, 80 (04)
  • [8] A phase I/II study of the combination of lapatinib and oral vinorelbine in HER2 positive metastatic breast cancer
    Chen, T. W-W
    Yeh, D-C
    Chao, T-Y
    Lin, C-H
    Chow, L. W-C
    Hsieh, Y-Y
    Huang, S-M
    Cheng, A-L
    Huang, C-S
    Lu, Y-S
    CANCER RESEARCH, 2016, 76
  • [9] A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer
    Chen, Tom Wei-Wu
    Yeh, Dah-Cherng
    Chao, Tsu-Yi
    Lin, Ching-Hung
    Chow, Louis Wing-Cheong
    Chang, Dwan-Ying
    Hsieh, Yao-Yu
    Huang, Shu-Min
    Cheng, Ann-Lii
    Lu, Yen-Shen
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (03) : 242 - 247
  • [10] N0337: Phase II study of capecitabine in combination with vinorelbine and trastuzumab for the first or second treatment of HER2+metastatic breast cancer
    Tan, W.
    Allred, J.
    Salim, M.
    Flynn, P.
    Kugler, J. W.
    Stella, P. J.
    Wiesenfeld, M.
    Bernath, A. M.
    Fitch, T. R.
    Perez, E. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345